Hamid Yousaif Qureshi: Japanese Scientists Develop Artificial Blood
Hamid Yousaif Qureshi, Expert in Medication Management and Patient-Centric Care, shared a post on LinkedIn:
“Researchers at Nara Medical University in Japan have been developing an experimental artificial blood substitute known as hemoglobin vesicles (HbV).
These are microscopic particles designed to carry oxygen in a way similar to red blood cells.
Each vesicle contains purified hemoglobin enclosed inside a lipid layer that functions like a simplified cell membrane.
One of the key advantages is compatibility. Natural blood must be carefully matched between donor and patient due to surface markers.
These vesicles do not carry those markers, meaning they could potentially be used across different blood types without matching.
Another major benefit is storage.
Donated blood typically lasts around 42 days, while these artificial vesicles can remain stable for much longer under controlled conditions.
This could make them useful in emergencies, disaster response, and areas where blood supply is limited.
However, this technology is still under development.
Natural blood performs many roles beyond oxygen transport, including clotting, immune response, and nutrient delivery.
Current versions of artificial blood are mainly designed to support oxygen delivery in specific situations.
Further research and clinical studies are ongoing to determine safety, effectiveness, and how this technology could be used in real-world medical care.
Source: Nara Medical University – research on hemoglobin vesicles.
Disclaimer: This content is for informational purposes only.
Courtesy:
MedStories.”
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 15:5810 Treating Fairly Research Awards – ASH
-
Apr 23, 2026, 15:51Abeer Alanazi: Secondary Stroke Prevention in Atrial Fibrillation
-
Apr 23, 2026, 15:46Brian O Mahony: What Causes the Battle Bettle Between AAV and the Liver?
-
Apr 23, 2026, 15:45Toong Youttananukorn: Excited to Share Our Poster at WFH 2026
-
Apr 23, 2026, 15:42Flora Peyvandi: Management of Antithrombotic Treatment in Atrial Fibrillation
-
Apr 23, 2026, 15:38William Aird: Do We Really Need MCH?
-
Apr 23, 2026, 15:35Andrea Baldini։ Aspirin Prophylaxis Is Effective But Still Off-Label In Some Countries
-
Apr 23, 2026, 14:52Anticoagulation Management and Outcomes in Patients with Cancer-Associated Small Venous Thromboembolism – JTH
-
Apr 23, 2026, 14:46Mital Jhaveri: Anticoagulant Approval and Uptake Timeline